Corey J Langer, MD
Drilon A et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med 2024;390(2):118-31. Abstract
Drilon A et al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discov 2023;13(3):598-615. Abstract
Liu G et al. Efficacy and safety of taletrectinib in patients with ROS1+ non-small cell lung cancer: The global TRUST-II study. WCLC 2024;Abstract MA06.03.
Solomon BJ et al. Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. ESMO 2023;Abstract 1372P.
Tangpeerachaikul A et al. Mutagenesis screens support potential best-in-class profile for selective, brain-penetrant, and TRK-sparing ROS1 inhibitor zidesamtinib (NVL-520). AACR 2024;Abstract LB182.
Wu YL et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med 2024;390(14):1265-76. Abstract
Ibiayi Dagogo-Jack, MD
Camidge DR et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein–overexpressing advanced nonsquamous EGFR-wildtype non–small cell lung cancer in the phase II LUMINOSITY trial. ASCO 2024;Abstract 103.
Camidge DR et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol 2024;42(25):3000-11. Abstract
Drilon A et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol 2023;41(2):385-94. Abstract
Felip E et al. IMpower010 5-y subgroup analysis and relapse patterns: Phase 3 study of atezolizumab vs BSC in stage II-IIIA NSCLC. WCLC 2024;Abstract OA01.04.
Goto K et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol 2023;41(31):4852-63. Abstract
Greisinger F et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: Update from the ARROW trial. Ann Oncol 2022;33(11):1168-78. Abstract
Heist RS et al. Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors. ASCO 2024;Abstract 3007.
Jänne PA et al. Adagrasib in non-small-cell lung cancer harboring KRASG12C mutation. N Engl J Med 2022;387:120-31. Abstract
Li Y et al. Adjuvant treatment options after neoadjuvant chemotherapy combined with immunotherapy and surgery in patients with non-small cell lung cancer. WCLC 2024;Abstract EP.08D.02.
Mok TSK et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. ASCO 2024;Abstract LBA8509.
Sacher A et al. Divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive NSCLC. WCLC 2024;Abstract OA14.06.
Skoulidis F et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021;384(25):2371-81. Abstract
Smit EF et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet 2024;25(4):439-54. Abstract
Yang G et al. Neoadjuvant chemotherapy is associated with optimized spatial landscape of tissue-resident memory T cells in non-small cell lung cancer. WCLC 2024;MA07.13.
Zhou C et al. A phase III study of rilertinib versus gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR-mutated NSCLC. WCLC 2024;Abstract OA02.04.
Zhou C et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med 2023;389(22):2039-51. Abstract